PA-PMI
17.6.2019 16:42:07 CEST | Business Wire | Press release
Project Management Institute (PMI) today released its 2019 Pulse of the Profession® In-Depth Report: AI Innovators: Cracking the Code on Project Performance . The report provides an in-depth look at how artificial intelligence (AI) is impacting organizations and the project management profession. Findings reveal that AI disruption is happening and at a large scale: 81 percent of respondents report their organization is being impacted by AI technologies; 37 percent say adopting AI technologies is a high priority for their organization; and project professionals say they expect the proportion of the projects they manage using AI will jump from 23 to 37 percent over the next three years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005558/en/
These insights from a survey of 551 project management practitioners globally show that the presence of AI technologies will continue to grow, requiring shifts in how projects are managed and how organizations implement strategy. The report identifies six AI technologies that are impacting organizations globally. The three AI technologies currently impacting the greatest number of organizations are:
- Knowledge-based systems: Understands the context of the data being processed, helping support human learning and decision making.
- Machine learning: Analyzes data to build models by detecting patterns, yielding improved decision making with minimal human intervention.
- Decision management: Creates an intelligent process or set of processes based on rules and logic to automate decision making.
Over the next three years, project professionals expect the impact of these AI technologies to grow:
- Expert systems: Emulates and mimics human intelligence, skills or behavior in a particular field, topic or skill.
- Deep learning: Builds, trains and tests neural networks that predict outcomes and/or classify unstructured data based on probabilities.
- Robotic process automation: Mimics and automates human tasks to support corporate processes.
In a recent Pulse of the Profession® report, PMI called for organizations to bolster their Project Management Technology Quotient (PMTQ) , which is a way of evaluating an organization’s ability to manage and integrate technology based on the needs of the organization or the project at hand. As organizations increasingly adopt AI technologies, having a strong PMTQ will be essential.
“What this report shows is that the time is now to start thinking about how organizations can leverage AI technologies to achieve project success,” said Michael DePrisco, vice president of global solutions at PMI. “Since project professionals are largely responsible for helping to implement change, they will play a critical role in influencing the adoption of these technologies in their organizations. Based on PMI research, we know that organizations with a high Project Management Technology Quotient (PMTQ) understand that capturing the value of AI will take more than simply rolling out the technology. It will require a new mindset, a learning culture and support from the top to establish an organizational infrastructure that leads to success.”
In fact, research by Accenture finds that most visionary organizations apply five key principles to their AI investments. Called the MELDS principles, they call on organizations to:
- Encourage the right Mindset
- Promote Experimentation
- Support actively involved Leadership
- Incorporate Data into strategy
- Cultivate new Skills
Organizations who embrace these five principles are called AI Innovators and are more likely than organizations that don’t embrace any of the principles (AI Laggards) to establish an organizational infrastructure that leads to project success. According to Pulse® data, there is a distinct payoff for organizations leading the way with AI. AI Innovators outperform AI Laggards on several key project metrics:
- Better on-time delivery: AI Innovators report they delivered 61 percent of their projects on time, versus 47 percent for AI Laggards.
- Superior benefits realization: AI Innovators report 69 percent of their projects realized 95 percent or more of their business benefits, compared to 53 percent of projects for AI Laggards.
- Higher ROI: AI Innovators report 64 percent of their projects met or exceeded their original ROI estimates, versus 52 percent of projects for AI Laggards.
Successful implementation of AI technology requires organizations to shift their priorities. Not only is it important to look at PMTQ as a measure of preparedness, but also how well an organization adheres to the MELDS principles. This will be especially important as more and more AI technologies are integrated into operations in the coming years.
Read more about 2019 Pulse of the Profession® In-Depth Report: AI Innovators: Cracking the Code on Project Performance at www.PMI.org/Pulse .
About the PMI Pulse of the Profession® Survey
This Pulse of the Profession® In-Depth research was conducted online in April/May 2019 among 551 project management practitioners globally.
About Project Management Institute (PMI)
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Founded in 1969, PMI delivers value for more than three million professionals working in nearly every country in the world through global advocacy, collaboration, education and research. We advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com creates online global communities that deliver more resources, better tools, larger networks and broader perspectives.
Visit us at www.PMI.org , www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190617005558/en/
Contact:
Mary Ortega Public Relations Specialist Project Management Institute 14 Campus Blvd. Newtown Square, PA 19073 Phone: +1 610 356 4600 X7030 E-mail: mary.ortega@pmi.org Website: www.pmi.org
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
